Flamel wins FDA nod for Bloxiverz
This article was originally published in Scrip
Executive Summary
The US FDA has granted French firm Flamel Technologies approval to market Bloxiverz (neostigmine methylsulfate) for intravenous use in the operating room to reverse the effects of non-depolarizing neuromuscular blocking agents after surgery.